Back to search

Article

Comparative Analysis of HER2 Immunohistochemistry (IHC) and Brightfield Dual-Color In Situ Hybridization (DISH) in Lymph Node Metastasized Breast Cancer

2024-09-04

Abstract excerpt

<title>Abstract</title> <p>Background The human epidermal growth factor receptor 2 (HER2) gene encodes a tyrosine kinase receptor, implicated in 15–20% of breast cancers. HER2 amplification is both prognostic and predictive of response to HER2-targeted therapy. IHC is the preferred initial test due to its cost-effectiveness and simplicity. While FISH is the gold standard test for HER2 amplification, it has sever...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6d21d6d3-8c43-5060-9d5a-62a51287e7c6
DOI
10.21203/rs.3.rs-4830804/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparative Analysis of HER2 Immunohistochemistry (IHC) and Brightfield Dual-Color In Situ Hybridization (DISH) in Lymph Node Metastasized Breast CancerDOI 10.21203/rs.3.rs-4830804/v1
Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersSemantic proximity
Discordance between Equivocal HER2 Immunohistochemistry and Fluorescence in Situ Hybridization Analysis among the Breast Carcinoma Patients in Bangladesh: A Series of 75 CasesSemantic proximity
Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity
Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studySemantic proximity
Validation of Dual-Color Dual In Situ Hybridization for HER2/neu Gene in Breast CancerSemantic proximity
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity
HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ HybridizationSemantic proximity
Light weight deep learning-based auto-quantification system for bright-filed HER2 dual in situ hybridization image analysisSemantic proximity
Histopathological and Clinical Features of HER2-Positive Breast Cancers across Hormone Receptor Subgroups: A Cross-Sectional AnalysisSemantic proximity
Discordance of HER2-low between primary tumors and matched distant metastases in breast cancerSemantic proximity
Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation PracticeSemantic proximity
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.